Video

Dr. Krug on Intra-Pleural Administration of GL-ONC1 in Patients With Malignant Pleural Effusion

Author(s):

Lee M. Krug, MD, associate attending physician, Division of Thoracic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, discusses a phase I study examining intra-pleural administration of GL-ONC1 in patients with malignant pleural effusion.

Lee M. Krug, MD, associate attending physician, Division of Thoracic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, discusses a phase I study examining intra-pleural administration of GL-ONC1 in patients with malignant pleural effusion.

In the dose escalation study, the majority of patients with malignant pleural effusion had malignant pleural mesothelioma, though some did have non—small cell lung cancer or breast cancer, Krug explains. GL-ONC1, an oncolytic virus genetically engineered with the insertion of the RUC-GFP, LacZ, and gUSA genes, is intra-pleurally administered to patients through a pleural catheter. Within a few days, patients undergo a video-assisted thoracoscopic surgery so that a physician can visualize the virus and take biopsy samples to document viral infections in the tumor cells.

Because GL-ONC1 is attenuated and removes several non-essential genes, it does not cause smallpox, Krug adds. Researchers hope the insertion of the virus will infect tumor cells, induce tumor cell lysis, and induce an immune reaction that could potentially contribute to the anti-tumor effect of GL-ONC1.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Addressing Unmet Needs in HER2+ Metastatic BTC
Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Apr 18th 2025 - Apr 19th 2026

online-activity
Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina
Video

Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina

Apr 17th 2025 - May 23rd 2025

online-activity
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota
Video

Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota

Apr 17th 2025 - May 23rd 2025

online-activity